Spyre Therapeutics, Inc. · NASDAQ:SYRE
The Vanguard Group's stake in Spyre Therapeutics, Inc. fell below 5% (Schedule 13G/A)
Event Mar 13, 2026 · Filed Mar 27, 2026
The Vanguard Group's stake in Spyre Therapeutics, Inc. fell below 5%, 0 shares, as a passive investor on Mar 13, 2026. Filed Mar 27, 2026 (Schedule 13G/A).
- Stake
- 0%
- Shares
- 0
- Intent
- Passive
- What changed
- Fell below 5%
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| The Vanguard Group | 0% | 0 |
Source
Related
- Spyre Therapeutics, Inc.
- The Vanguard Group
- Spyre Therapeutics, Inc. shareholders
- Schedule 13G · The Vanguard Group · Jul 29, 2025
- Schedule 13D/A · Harwin Peter Evan · Oct 9, 2026
- Form 4 · Burrows Scott L · Oct 2, 2026
- Form 4 · King-Jones Heidy · Oct 2, 2026
- Form 4 · Turtle Cameron · Oct 2, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Oct 1, 2026